SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.

Andere talen Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Aandelen

6990

CNE1000062J1

Beurs gesloten - Hong Kong S.E. Andere beurzen 10:08:10 21-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
176,6 ^HKD	+3,27%		+2,32%	+71,62%

08/05	Sichuan Kelun-biotech Biopharmaceutical wil 3,6 miljoen aandelen plaatsen; sluit inschrijvingsovereenkomst voor 4,4 miljoen aandelen	MT
06/05	Kelun-Biotech's medicijn tegen longkanker gaat door naar Fase 2 testen in VS; aandelen stijgen 8%	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Sichuan Kelun-biotech Biopharmaceutical to Place 3.6 Million Shares; Inks Subscription Deal for 4.4 Million Shares	08/05
Kelun-Biotech's Lung Cancer Drug Advances to Phase 2 Trials in US; Shares Up 8%	06/05
Sichuan Kelun-Biotech Buys Structured Deposits Worth 680 Million Yuan	15/04
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Study Results for Core Product Scituzumab Turumotecan (SAC-TMT) at AACR Annual Meeting 2024	08/04
Kelun-Biotech Shrinks Loss by 7% in 2023	26/03
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	25/03
China Healthcare Stocks Rally on Hopes for Government Support	14/03
China Grants Breakthrough Therapy Designation for Kelun-Biotech's Breast Cancer Treatment	13/03
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Its Core Product SKB264 (MK-2870) Granted Breakthrough Therapy Designation for First-Line Treatment of Unresectable Locally Advanced, Recurring or Metastatic Pd-L1 Negative Tnbc by the National Medical Products Administration	13/03
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Key Product A400 Granted Fast Track Designation by the US Food and Drug Administration	11/03
Kelun-Biotech Shares Start Trading in Shanghai's Southbound Stock Connect	04/03
Kelun-Biotech Licensee Starts Phase 3 Trials for Cancer Treatment; Shares Rise 5%	23/02
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Collaboration with Merck Sharp & Dohme LLC	23/02
Kelun-Biotech Chosen as Constituent Stock of Hang Seng Indexes; Shares Fall 3%	19/02
Kelun-Biotech Controlling Shareholder Ups Stake; Shares Rise 4%	23/01
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.(SEHK:6990) added to S&P Global BMI Index	18/12
China Accepts Kelun-Biotech's Application for Triple-Negative Breast Cancer Treatment; Shares Fall 4%	11/12
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces New Drug Application for Core Product SKB264 (MK-2870) Accepts by the National Medical Products Administration	11/12
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to Present the Updated Efficacy and Safety Results from Core Product	30/11
US FDA Grants Orphan Drug Designation for Kelun-Biotech's Solid Tumor Drug	27/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Aandelen

6990

CNE1000062J1

Andere talen

Filters